Implementation Risk-Based Prevention Cross-Contamination ...
Manufacturers should be mindful that cross contamination controls implemented previously may not adequately assure control of the cross-contamination risk in the context of the HBEL approach. Additional observation of working practices, investigation and analysis may be required to provide full practical confidence in the effectiveness of controls.
Download Implementation Risk-Based Prevention Cross-Contamination ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Infection Prevention and Control Assessment Tool for ...
www.cdc.govInfection Prevention and Control Assessment Tool for Hemodialysis Facilities This tool is intended to assist in the assessment of infection control programs and practices in dialysis facilities. In order ... Note: Due to potential cross -contamination and ...
CLEANING VALIDATION WITH RISK ASSESSMENT
www.usp-pqm.orgof Cleaning Validation and Risk Assessment ISPE Baseline Guide for The Risk -Based Manufacture of Pharmaceutical Products (Risk- MaPP) (2009) – CV Related Highlights Risk MaPP Guide Provides a Risk Based Approach Based on ICH Q9 for Setting Health Based Cross-Contamination and CV Limits Within Multi-Product Facilities.
Risk Assessment Under BRC - International Food Safety and ...
www.ifsqn.com5.3.3 A documented risk assessment shall be carried out to identify routes of contamination and establish documented policies and procedures for handling raw materials, intermediate and finished products to ensure cross-contamination is avoided.
Case Studies of Risk Assessment for Cross Contamination
www.ema.europa.euassessment process Use of data is essential to a robust risk assessment Cleaning is just one mode of cross contamination HBEL’s are used to set cleaning limits as well as for assessment of airborne and mechanical transfer Embed the process into the Quality Management System to ensure it is a lifecycle approach
Construction COVID-19 Risk Assessment - Siemens
assets.new.siemens.comVirus and cross contamination) “Anyone who meets one of the following criteria should not come to site: Op has a high temperature or a new persistent cough - follow the 4 4 16 Ops with family to maintain government guidelines on isolation, refer to reference information attached. Medical based risk assessment to be carried out, all high-
Cross Contamination & the EU GMP Guide
www.pharmout.net3.6 Cross-contamination should be prevented for all products by appropriate design and operationof manufacturing facilities. The measures to prevent cross-contamination should be commensurate with the risks. Quality Risk Management principles should be used to assess and control the risks.